drugset / Trial / NCT05939622
Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19
RandomizedSequentialSingle-blindTreatment
Summary
to assess executive network using resting-state fMRI and patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking the drug in comparison with placebo in patients with post-COVID asthenic syndrome.
Timeline
- Start
- 2022-05-18
- Primary completion
- 2022-12-20
- Completion
- 2022-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EMOXYPINE | Small molecule | 500 mg | Intramuscular |
| Subject | Meldonium | Small molecule | 500 mg | Intramuscular |